Annual report pursuant to Section 13 and 15(d)

Note 4 - Acquisitions (Details Textual)

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands										11 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 04, 2019	Aug. 01, 2018	Jul. 02, 2018	Feb. 01, 2018	Jan. 02, 2018	Sep. 05, 2017	Aug. 01, 2016	Jul. 01, 2016	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Payments to Acquire Businesses, Net of Cash Acquired, Total												$ 289,492			$ 67,851	$ 253,785
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability															(26,600)	$ (11,800)
Business Combination, Contingent Consideration, Liability, Total	$ 12,600									$ 12,600	$ 12,600	12,600	$ 12,600	$ 12,600
QT Holdings Corporation [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 20,404										20,462
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	51,000			51,000						51,000	51,000	51,000	51,000	51,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount				0
Goodwill, Purchase Accounting Adjustments													4,700	4,691
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	12,256			20,000						12,256	12,256	12,256	12,256	12,256
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles														(7,744)
Business Combination, Consideration Transferred, Total				25,604										25,762
Business Combination, Consideration Transferred, Liabilities Incurred				$ 5,200										5,300
QT Holdings Corporation [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life				14 years
Exosome Diagnostics, Inc [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	251,623		$ 251,825							251,600
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	325,000		325,000							325,000	325,000	$ 325,000	325,000	325,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount			0
Goodwill, Purchase Accounting Adjustments											8,770
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability											2,000
Business Combination, Consideration Transferred, Total			253,625								255,423
Business Combination, Consideration Transferred, Liabilities Incurred			1,800								3,800
Exosome Diagnostics, Inc [Member] \| Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			250,000
Exosome Diagnostics, Inc [Member] \| Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			45,000
Exosome Diagnostics, Inc [Member] \| Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			30,000
Exosome Diagnostics, Inc [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life												15 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			180,000
Exosome Diagnostics, Inc [Member] \| Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life												15 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	58,000									58,000	58,000	$ 58,000	58,000	58,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles											58,000
Exosome Diagnostics, Inc [Member] \| Developed Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	105,000									105,000	105,000	$ 105,000	105,000	105,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles											(75,000)
Exosome Diagnostics, Inc [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life												14 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	2,300									2,300	2,300	$ 2,300	2,300	2,300
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles											2,300
B-MoGen [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 17,448
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 38,000	38,000								$ 38,000	$ 38,000	38,000	$ 38,000	$ 38,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount		0
Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value		1,400
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain		3,700
Business Combination, Consideration Transferred, Liabilities Incurred		$ 5,500
B-MoGen [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life		14 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 14,000
B-MoGen [Member] \| Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 400
Trevigen Inc. [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total							$ 10,600					10,644
Business Acquisition, Goodwill, Expected Tax Deductible Amount							$ 0
Business Combination, Consideration Transferred, Total												10,644
Business Combination, Consideration Transferred, Liabilities Incurred
Atlanta Biologicals [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total												51,274
Business Acquisition, Goodwill, Expected Tax Deductible Amount						$ 0
Business Combination, Consideration Transferred, Total						$ 51,300						51,274
Business Combination, Consideration Transferred, Liabilities Incurred
Atlanta Biologicals [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life						13 years
Atlanta Biologicals [Member] \| Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life						15 years
Atlanta Biologicals [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life						12 years
Eurocell Diagnostics, SAS [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total												5,933
Business Acquisition, Goodwill, Expected Tax Deductible Amount					$ 0
Business Combination, Consideration Transferred, Total					7,300							7,329
Payments to Acquire Businesses, Gross					6,000
Business Combination, Consideration Transferred, Liabilities Incurred					$ 1,300							1,396
Eurocell Diagnostics, SAS [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life					7 years
Advanced Cell Diagnostics (ACD) [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total								$ 247,000				247,038
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High								75,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount								0
Business Combination, Consideration Transferred, Total												287,638
Payments to Acquire Businesses, Gross								258,000
Business Combination, Consideration Transferred, Liabilities Incurred								$ 11,000				3,600
Business Combination, Consideration Transferred, Employee Vesting Period								1 year 180 days
Advanced Cell Diagnostics (ACD) [Member] \| Pre-acquisition Services [Member]
Business Combination, Consideration Transferred, Liabilities Incurred								$ 3,600
Advanced Cell Diagnostics (ACD) [Member] \| Future Services [Member]
Business Combination, Consideration Transferred, Liabilities Incurred								7,400
Advanced Cell Diagnostics (ACD) [Member] \| The 2016 Revenue Equal or Exceed $30 Milliom [Member]
Business Combination, Contingent Consideration, Liability, Total								25,000
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue								30,000
Advanced Cell Diagnostics (ACD) [Member] \| The 2017 Revenues Equal or Exceed $45 Million [Member]
Business Combination, Contingent Consideration, Liability, Total								50,000
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue								$ 45,000
Space [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total									$ 6,700			6,747
Business Acquisition, Goodwill, Expected Tax Deductible Amount									0
Business Combination, Consideration Transferred, Total												9,003
Payments to Acquire Businesses, Gross									9,000
Business Combination, Consideration Transferred, Liabilities Incurred									$ 2,300			$ 2,256